LUND, Sweden, Aug. 13, 2020 /PRNewswire/ -- Immunovia invites
to a teleconference (in English) for investors, analysts and media
on Thursday, August 20th,
2020 at 16:30 CET. Immunovia will
publish the company's interim report on August 20th, 2020 at 16:00 CET.
Mats Grahn, CEO will present
Immunovia and comment on the interim report for the period January
- June 2020 followed by a Q&A
session. Please call in a few minutes in advance.
To attend, please dial-in at one of the numbers below and
provide the conference code Immunovia to the
operator:
Conference Numbers:
Sweden: +46 (0) 8-50520424
United States:
+1-212-999-6659
France: +33 (0) 1-7037-7166
Denmark: +45-3272-9273
Germany: +49 (0)
30-3001-90612
Spain: +34-91-787-0777
Netherlands: +31 (0)
20-708-5073
Norway:
+47-2-156-3318
Austria: +43 (0)
12530807
Switzerland: +41 (0)
22-592-7915
UK (Standard International Access): +44 (0) 20-3003-2666
Conference Code: (to provide to the operator)
Immunovia
Immunovia Webcast:
https://channel.royalcast.com/immunovia/#!/immunovia/20200820_1
There will be an MP3-file available at Immunovia's webpage under
Investors/Financial Reports
(http://immunovia.com/investors/financial-reports/) for those who
want to listen to the telephone conference afterwards. The file
will be available within two hours after the conference has
ended.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q3
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
For more information, please contact:
Julie Silber
Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/invitation-to-presentation-of-immunovia-s-interim-report-january---june-2020-on-august-20--2020,c3167678
The following files are available for download:
https://mb.cision.com/Main/13121/3167678/1290244.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/invitation-to-presentation-of-immunovias-interim-report-january---june-2020-on-august-20-2020-301111569.html
SOURCE Immunovia AB